Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
- PMID: 9360927
- DOI: 10.1126/science.278.5341.1295
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
Abstract
The hypothesis that quiescent CD4+ T lymphocytes carrying proviral DNA provide a reservoir for human immunodeficiency virus-type 1 (HIV-1) in patients on highly active antiretroviral therapy (HAART) was examined. In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+ T lymphocytes. The frequency of resting CD4+ T cells harboring latent HIV-1 was low, 0.2 to 16.4 per 10(6) cells, and, in cross-sectional analysis, did not decrease with increasing time on therapy. The recovered viruses generally did not show mutations associated with resistance to the relevant antiretroviral drugs. This reservoir of nonevolving latent virus in resting CD4+ T cells should be considered in deciding whether to terminate treatment in patients who respond to HAART.
Comment in
-
HIV survives drug onslaught by hiding out in T cells.Science. 1997 Nov 14;278(5341):1227. doi: 10.1126/science.278.5341.1227. Science. 1997. PMID: 9411749 No abstract available.
Similar articles
-
A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.J Clin Invest. 2000 Apr;105(7):995-1003. doi: 10.1172/JCI9006. J Clin Invest. 2000. PMID: 10749578 Free PMC article.
-
Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.J Virol. 2002 Sep;76(18):9481-92. doi: 10.1128/jvi.76.18.9481-9492.2002. J Virol. 2002. PMID: 12186930 Free PMC article.
-
HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.JAMA. 2001 Jul 11;286(2):196-207. doi: 10.1001/jama.286.2.196. JAMA. 2001. PMID: 11448283
-
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review.
-
New Approaches to Multi-Parametric HIV-1 Genetics Using Multiple Displacement Amplification: Determining the What, How, and Where of the HIV-1 Reservoir.Viruses. 2021 Dec 10;13(12):2475. doi: 10.3390/v13122475. Viruses. 2021. PMID: 34960744 Free PMC article. Review.
Cited by
-
HIV-1 integration sites in CD4+ T cells during primary, chronic, and late presentation of HIV-1 infection.JCI Insight. 2021 May 10;6(9):e143940. doi: 10.1172/jci.insight.143940. JCI Insight. 2021. PMID: 33784259 Free PMC article.
-
Cellular Activation, Differentiation, and Proliferation Influence the Dynamics of Genetically Intact Proviruses Over Time.J Infect Dis. 2022 Apr 1;225(7):1168-1178. doi: 10.1093/infdis/jiab291. J Infect Dis. 2022. PMID: 34037766 Free PMC article.
-
Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection.PLoS One. 2012;7(8):e44163. doi: 10.1371/journal.pone.0044163. Epub 2012 Aug 30. PLoS One. 2012. PMID: 22957000 Free PMC article.
-
Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening.Front Pharmacol. 2020 Jun 17;11:905. doi: 10.3389/fphar.2020.00905. eCollection 2020. Front Pharmacol. 2020. PMID: 32625097 Free PMC article.
-
HIV-1 antiretroviral drug therapy.Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161. doi: 10.1101/cshperspect.a007161. Cold Spring Harb Perspect Med. 2012. PMID: 22474613 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials